A new cutting-edge treatment for patients with chronic obstructive pulmonary disease (COPD) has been carried out by experts at Royal Brompton and Chelsea and Westminster hospitals in London as part of a research trial. COPD is an umbrella term for a collection of conditions causing lung damage, including chronic bronchitis and emphysema, and affects around three million people in the UK.
Apr 09, 2025 - Discover the latest advancements in COPDtreatment in this informative post. Explore emerging therapies, medications, and interventions that improve symptoms and enhance quality of life. Stay up to date on the ever-evolving landscape of COPD management.
An incredible 238 patients have now taken part in a clinical trial at the National Institute for Health and Care Research (NIHR) Leicester Biomedical Research Centre (BRC), offering hope for newtreatments for people suffering from chronic obstructive pulmonary disease (COPD). COPD is a devastating long-term condition that affects the lungs with symptoms including shortness of breath and ...
Ohtuvayre is the first new inhaled COPD therapy approved in over two decades. COPD is a chronic inflammatory condition that limits airflow from the lungs and can make breathing difficult. The medication is approved for use alone or alongside other COPDtreatments.
This development could open up new research opportunities for the COPD community and provide an alternative treatment option for people who do not respond well to current treatments This treatment can help people with COPD. The medicine may help lessen COPD symptoms, make breathing easier, and lead to fewer hospital visits.
The most impactful changes to the 2025 GOLD Report pertain to chronic obstructive pulmonary disease (COPD) management, specifically the addition of 2 newtreatment options, ensifentrine and dupilumab, that were approved for use by the FDA in June 2024 and September 2024, respectively.
Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark phase 3 studies showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life Dupixent is the first newtreatment approach ...
In 2025, several new drugs are redefining COPDtreatment. Learn about the biologics Nucala and Dupixent, the dual-acting Ohtuvayre, and who they can help.
